The median calculated twicedaily dose of enoxaparin was 60 mg (range 50–120). The primary outcome (anti-factor Xa level between 0.2 and 0.5 IU/mL) was achieved in 91% of patients (21 of 23 ...

Recent data have shown that fondaparinux, a selective factor Xa inhibitor, is noninferior to enoxaparin for short-term prevention of adverse cardiovascular outcomes in patients with non-ST-segment ...

RESULTS: A weight-based dosage range of enoxaparin 50–120 mg twice daily (median 60) was given to 23 patients. The mean BMI was 46.4 kg/m2. The initial mean anti-factor Xa level (measured after ...